In one study performed by the Gynecology Oncology Group, 61 patients with advanced or recurrent uterine cancer were treated with megestrol and tamoxifen. The complete response rate was 21% and 5.4% had a partial response. The average survival was 14 months.
Overall survival after recurrence in 27 patients with recurrences earlier than 12 months. The incidence of uterine endometrial carcinoma, already the most common. . Clinical characteristics of the patients with recurrent endometrial cancer.
An estimated 319,600 new cases of endometrial cancer (EC) occurred. The 3-
For uterine cancer, the staging system developed by the International Federation of Obstetrics. Recurrent cancer is cancer that has returned after treatment.